Mon, Apr 21, 2014, 10:24 AM EDT - U.S. Markets close in 5 hrs 36 mins

Recent

% | $
Quotes you view appear here for quick access.

Nanosphere, Inc. (NSPH) Message Board

  • n_s_sherlock n_s_sherlock Apr 15, 2013 11:37 AM Flag

    And NSPH's share of the market gets smaller still

    "FDA Clears Luminex xTAG Gastrointestinal Panel on MagPix Platform
    April 15, 2013

    By a GenomeWeb staff reporter

    NEW YORK (GenomeWeb News) – Luminex said today that it has received clearance from the US Food and Drug Administration for its MagPix instrument and xTAG Gastrointestinal Pathogen Panel, or GPP.

    The xTAG GPP assay is the first clinical assay to be cleared in the US for the MagPix instrument. It also is the first FDA-cleared test that can simultaneously detect 11 common viral, bacterial, and parasitic causes of infectious gastroenteritis from a single stool sample, Luminex said.

    Specifically, xTag GPP tests for Campylobacter; Clostridium difficile Toxin A/B; Escherichia coli 0157; enterotoxigenic E. coli LT/ST; Shiga-like toxin-producing E. coli stx1/stx2; Salmonella; Shigella; Rotavirus A; Norovirus GI/GII; Giardia lamblia; and Cryptosporidium.

    FDA in January cleared the xTAG GPP test for use on the previously approved Luminex 100/200 system.

    The company said that MagPix is an easy-to-use and versatile multiplexing platform capable of performing qualitative and quantitative analysis of proteins and nucleic acids in a variety of sample matrices.

    In addition, MagPix is compact, making it attractive to laboratories with limited bench space, and can perform up to 50 different tests in a single reaction volume, greatly reducing sample input, reagents, and labor while improving productivity, Luminex said."

    Sentiment: Strong Sell

    SortNewest  |  Oldest  |  Most Replied Expand all replies
 
NSPH
1.85+0.02(+1.09%)10:24 AMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.